Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients
We are conducting a study to look at the effects of a vaccine that prevents human papillomavirus (HPV) among people who receive kidney transplants. People who receive organ transplants are at increased risk for cancers due to the drugs routinely given after transplant to suppress/”lower” the immune system’s reaction to the new kidney . Such cancers include those caused by HPV including cervical, vulvar, vaginal, penile, throat, and anal cancers. The Gardasil® 9 HPV vaccine has been shown to be effective in preventing HPV infection that causes these cancers when given to people up to the age of 45.
In this study, we want to test if giving the Gardasil® 9 vaccine before receiving a kidney transplant will continue to protect the body against HPV infection, even when the person takes medication to suppress the immune system after their transplant. We would like to enroll 180 volunteers into this study.
You may be eligible if you:
-
Are between the ages of 18 and 49 and not pregnant
-
Are expecting to receive a kidney transplant within the next 12 months
-
Have a potentially compatible donor, OR have a high priority on the transplant waiting list to receive a deceased donor kidney
You may be reimbursed up to $500 for your time, travel, and other costs related to your participation.
If you are interested and wish to know more you can contact a study coordinator at your preferred location from the list below:
CEDARS-SINAI MEDICAL CENTER - Los Angeles, California
NORTHWESTERN UNIVERSITY - Chicago, Illinois
UNIVERSITY ALABAMA BIRMINGHAM - Birmingham, Alabama
UNIVERSITY OF CALIFORNIA SAN FRANCISCO - San Francisco, California
This trial is being sponsored by the National Cancer Institute’s Division of Cancer Prevention and coordinated by Northwestern University.
